Spots Global Cancer Trial Database for Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Official Title: Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib

Study ID: NCT04217993

Conditions

Primary Myelofibrosis (PMF)

Post-polycythemia Vera Myelofibrosis(Post-PV MF)

Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

Interventions

Jaktinib hydrochloride tablets

Study Description

Brief Summary: This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.

Detailed Description: dose exploration: It is planned to enroll about 6 subjects. According to the baseline value of platelet count at the time of enrollment, different doses (100mg Qd or 150mg Qd or 200mg Qd or 100mg Bid) of Jaktinib Hydrochloride Tablets will be Treated. The trial is in progress Adjust the dose according to relevant laboratory indicators. When at least one subject has a spleen volume reduction of ≥35% from the baseline, the sponsor and the investigator will jointly decide whether to enter the extended study part. Extended research: It is planned to enroll about 43 subjects, and the initial dosage of Jaktinib Hydrochloride Tablets is planned to be 100mg Bid.